Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia

New England Journal of Medicine

Volumn 380, Issue 1, 2019, Pages 11-22

  Bhatt, Deepak L ^a   Steg, P Gabriel ^b,c   Miller, Michael ^d   Brinton, Eliot A ^e   Jacobson, Terry A ^f   Ketchum, Steven B ^g   Doyle, Ralph T ^g   Juliano, Rebecca A ^g   Jiao, Lixia ^g   Granowitz, Craig ^g   Tardif, Jean Claude ^h   Ballantyne, Christie M ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INSERM   (France)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Utah Lipid Center   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Amarin Pharma   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID;

AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM BLEEDING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; FOLLOW UP; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; RISK FACTOR; SECONDARY PREVENTION;

AGED; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SECONDARY PREVENTION; TRIGLYCERIDES;

EID: 85058215650     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1812792     Document Type: Article

References (38)

1. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304: 1350-7.
2. Nambi V, Bhatt DL. Primary prevention of atherosclerosis: time to take a selfie? J Am Coll Cardiol 2017; 70: 2992-4.
3. Vaduganathan M, Venkataramani AS, Bhatt DL. Moving toward global primordial prevention in cardiovascular disease: the heart of the matter. J Am Coll Cardiol 2015; 66: 1535-7.
4. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
5. Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J 2015; 36: 774-6.
6. Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes 2016; 9: 100-8.
7. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab 2018; 103: 3019-27.
8. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2018 September 17 (Epub ahead of print).
9. Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc 2018; 7(15): e008740.
10. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 2018; 72: 330-43.
11. The ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367: 309-18.
12. The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018; 379: 1540-50.
13. Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 2018; 3: 225-34.
14. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-8.
15. Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol 2017; 40: 138-48.
16. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108: 682-90.
17. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110: 984-92.
18. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013; 13: 37-46.
19. Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol 2017; 91: 1-9.
20. Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta 2016; 1858: 3131-40.
21. Sherratt SCR, Mason RP. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids 2018; 212: 73-9.
22. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating lowdensity lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013; 310: 2061-8.
23. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-12.
24. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998; 147: 783-90.
25. Itakura H, Yokoyama M, Matsuzaki M, et al. Relationship between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 2011; 18: 99-107.
26. Bays HE, Ballantyne CM, Doyle RT Jr, Juliano RA, Philip S. Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat 2016; 125: 57-64.
27. Chang CH, Tseng PT, Chen NY, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2018; 129: 1-12.
28. Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of highdensity lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol 2018; 41: 1281-8.
29. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res 2014; 114: 1929-43.
30. Doi M, Nosaka K, Miyoshi T, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol 2014; 176: 577-82.
31. Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol 2017; 70: 537-44.
32. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 2015; 242: 357-66.
33. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119-31.
34. Verma S, Leiter LA, Bhatt DL. CANTOS ushers in a new calculus of inflammasome targeting for vascular protection - and maybe more. Cell Metab 2017; 26: 703-5.
35. Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. J Am Coll Cardiol 2017; 70: 2171-85.
36. Budoff M, Brent Muhlestein J, Le VT, May HT, Roy S, Nelson JR. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: rationale and design of the EVAPORATE study. Clin Cardiol 2018; 41: 13-9.
37. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
38. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018 November 7 (Epub ahead of print).